HCPCS Code J3262: Injection, Tocilizumab, 1 mg

Improve your claim success rate for HCPCS code J3262. Read about applicable modifiers, billing, and documentation guidelines for HCPCS code J3262 here.

Use Code

## **What is a tocilizumab injection?** HCPCS code J3262 for injection tocilizumab 1 mg, as maintained by CMS, falls under drugs administered by injection. This cod refers to the intravenous administration of tocilizumab, a biologic monoclonal antibody targeting interleukin-6 (IL-6). Commonly known by the brand name ACTEMRA®, tocilizumab treats rheumatoid arthritis, giant cell arteritis, cytokine release syndrome, and systemic juvenile idiopathic arthritis. This medication is typically administered in clinical settings through intravenous administration, dosed according to the patient's body weight and specific condition. The infusion usually takes around one hour, supervised by healthcare professionals who monitor for potential hypersensitivity reactions or rare but serious complications such as gastrointestinal perforation. Billing with HCPCS code J3262 allows accurate reimbursement, as it precisely matches the 1 mg administered per billing unit, ensuring alignment with pharmaceutical pricing.

## **J3262 documentation requirements** Proper documentation is critical when billing HCPCS code J3262. Documentation must accurately reflect all relevant details, including: ### **Diagnosis and indication** Clearly document the ICD-10 diagnosis code, such as rheumatoid arthritis or systemic juvenile idiopathic arthritis, confirming medical necessity for the drug. ### **Dose administered** Document the exact total dose in milligrams, ensuring alignment with the billed units (each unit equals exactly 1 mg as maintained). ### **Intravenous administration details** Record the infusion route, duration (start and stop times), and method, explicitly noting intravenous administration. ### **Patient monitoring and reactions** Record patient monitoring details, including vital signs and any hypersensitivity reactions or injection site reactions observed during or after administration. ### **Drug wastage documentation** Clearly document any drug wastage from single-dose vials, indicating whether the JW modifier (drug wasted) or JZ modifier (no waste) applies.

## **J3262 billing requirements** Billing HCPCS code J3262 for injection tocilizumab 1 mg as maintained by CMS requires adherence to specific guidelines to ensure accurate reimbursement and compliance: ### **Exact unit reporting** Bill precisely 1 mg per unit of tocilizumab administered, without rounding. ### **Modifier usage (JW/JZ/JB)** Apply modifiers JW if the drug is discarded, JZ if no drug discarded, or JB when administered subcutaneously, according to CMS guidelines. ### **Administration code pairing** Pair J3262 appropriately with CPT 96365 to represent intravenous infusion administration during the patient encounter. ### **NDC reporting** Include the correct National Drug Code (NDC) on all Medicare Part B claims, as it is mandatory for biologics billing. ### **Prior authorization** Confirm and document prior authorization, as most payers require it for biologic drugs administered by injection.

## **J3262 applicable modifiers** Modifiers required for correct billing of HCPCS code J3262 include: 1. **JW modifier**: Used when a portion of the drug is discarded/not administered to any patient from single-dose containers. 1. **JZ modifier**: Indicates no drug amount was discarded, mandated since July 1, 2023. 1. **JB modifier**: Required specifically when tocilizumab is given subcutaneously rather than intravenously. Providers must adhere to these modifier rules to ensure claims accuracy and compliance.

## **Other relevant codes** Providers frequently encounter related CPT and HCPCS codes alongside J3262 when billing for intravenous biologics or services related to autoimmune and inflammatory conditions: - **96365**: Intravenous infusion administration, initial hour; commonly billed with biologic infusions. - **J0129**: Injection, abatacept, per 10 mg; another biologic infusion therapy for autoimmune conditions. - **J1745**: Injection, infliximab, 10 mg; intravenous biologic for inflammatory autoimmune diseases. - **J3357**: Injection, ustekinumab, 1 mg; administered intravenously for various inflammatory diseases.

Frequently asked questions

Tocilizumab (ACTEMRA®) is used to treat inflammatory conditions such as rheumatoid arthritis, giant cell arteritis, cytokine release syndrome, and systemic juvenile idiopathic arthritis.

Yes, ACTEMRA infusions generally have Medicare coverage, provided documentation meets the medical necessity criteria established by CMS guidelines.

The generic name for ACTEMRA is tocilizumab.